Axitinib 1 mg, 5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 1 mg, 5 mg

Reference Brands: Inlyta®(EU & US)

Category: Oncology Cancer Care

Axitinib 1 mg and 5 mg Tablets are used in oncology for the treatment of metastatic renal cell carcinoma (RCC). Available under the brand name Inlyta®, Axitinib is a tyrosine kinase inhibitor that targets VEGF receptors to inhibit tumor growth. It is used as a second-line therapy after the failure of prior treatments like sunitinib or pazopanib. Available in oral tablet form, it is typically taken twice daily.

Product Description: Axitinib 1 mg and 5 mg Tablets are a key treatment for metastatic renal cell carcinoma (RCC), primarily used as a second-line therapy for patients who have failed prior treatments like sunitinib or pazopanib. As a tyrosine kinase inhibitor, Axitinib targets the VEGF receptors involved in tumor angiogenesis, thus slowing the growth of cancer cells. Approved under the brand name Inlyta® in both the U.S. and EU, Axitinib is essential in oncology B2B portfolios for advanced RCC treatment. It is typically administered twice daily in oral tablet form at doses of 1 mg or 5 mg.